Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LINE and 80,000+ other tickers.
See exactly how LINE's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LINE and 80,000+ other tickers.
Lineage, Inc. operates as a real estate investment trust (REIT) primarily focused on temperature-controlled warehouse properties. Its business activities are organized into two main divisions: Global Warehousing and Global Integrated Solutions. The Global Warehousing segment manages a portfolio of industrial real estate assets that provide refrigerated and frozen storage services to its customers. The Global Integrated Solutions segment, in contrast, specializes in delivering tailored cold-chain logistics services. This company was established in 2008 and has its corporate headquarters situated in Novi, Michigan.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Value Line, Inc. (NASDAQ – VALU ) announced today that its Board of Directors declared on July 17, 2026 a quarterly cash dividend of $0.35 per common share, payable on August 11, 2026, to stockholders of record on July 27, 2026. The Company has 9,383,573 shares of common stock outstanding as of July 17, 2026.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on COR1, the Company's allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, Lineage is deploying its ophthalmology and cell manufacturing expert.
Lineage remains a Buy, offering a margin of safety and re-rating potential despite near-term macro and operational headwinds. Q1 saw AFFO per share decline 9.3% to $0.78, but guidance for Adj. EBITDA ($1.25–$1.3B) and AFFO per share ($2.75–$3.00) were maintained. LINE's cost reduction plan and automation investments target $110M annualized EBITDA improvement in 3–5 years, supporting long-term upside.
MIDDLEBURY, Ind., July 08, 2026 (GLOBE NEWSWIRE) -- Grand Design RV, the fast-growing innovator of travel trailers, 5th wheels and motorized RVs, today announced the launch of the all-new Lineage series E, expanding its award-winning motorized portfolio with a new Class C motorhome designed to deliver premium comfort, practical functionality and confidence on the road. Built on the dependable Ford® E-450 chassis, the Series E brings Grand Design's owner-focused approach to one of the most established and accessible segments of the motorized RV market.